Bionet (1784) - Total Liabilities
Based on the latest financial reports, Bionet (1784) has total liabilities worth NT$822.58 Million TWD (≈ $25.92 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Bionet - Total Liabilities Trend (2017–2025)
This chart illustrates how Bionet's total liabilities have evolved over time, based on quarterly financial data. See 1784 working capital efficiency to evaluate short-term liquidity relative to the company's equity base.
Bionet Competitors by Total Liabilities
The table below lists competitors of Bionet ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Tung Ho Textile Co Ltd
TW:1414
|
Taiwan | NT$1.04 Billion |
|
Nava Nakorn Public Company Limited
BK:NNCL
|
Thailand | ฿1.11 Billion |
|
Eimco Elecon (India) Limited
NSE:EIMCOELECO
|
India | Rs507.07 Million |
|
Garuda Metalindo Tbk PT
JK:BOLT
|
Indonesia | Rp581.39 Billion |
|
Eagle Cold Storage Enterprise Co Ltd
TWO:8905
|
Taiwan | NT$750.47 Million |
|
Icares Medicus Inc
TWO:6612
|
Taiwan | NT$1.21 Billion |
|
GOLCONDA GOLD LTD
F:Y87
|
Germany | €15.40 Million |
|
Calitech Co Ltd
TWO:6532
|
Taiwan | NT$294.20 Million |
Liability Composition Analysis (2017–2025)
This chart breaks down Bionet's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Bionet market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.62 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.65 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.27 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Bionet's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Bionet (2017–2025)
The table below shows the annual total liabilities of Bionet from 2017 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | NT$822.58 Million ≈ $25.92 Million |
+8.18% |
| 2024-12-31 | NT$760.40 Million ≈ $23.96 Million |
+21.38% |
| 2023-12-31 | NT$626.47 Million ≈ $19.74 Million |
+21.89% |
| 2022-12-31 | NT$513.97 Million ≈ $16.19 Million |
+9.78% |
| 2021-12-31 | NT$468.19 Million ≈ $14.75 Million |
+5.11% |
| 2020-12-31 | NT$445.44 Million ≈ $14.03 Million |
-1.86% |
| 2019-12-31 | NT$453.87 Million ≈ $14.30 Million |
+2.43% |
| 2018-12-31 | NT$443.09 Million ≈ $13.96 Million |
-2.26% |
| 2017-12-31 | NT$453.33 Million ≈ $14.28 Million |
-- |
About Bionet
BIONET Corp. engages in the cell therapy business in Taiwan and internationally. The company offers stem cell banking services, such as stem cell storage, mesenchymal stem cell storage, dental stem cell storage, adipose stem cell, and PBSC and immune cells; and genetic testing services. It also provides storage and application of hematopoietic stem cells; regenerative medicine, analytical testing… Read more